| 1 |
Clinical development and global collaboration of NS101: A novel monoclonal antibody therapeutic for sensorineural hearing loss through synaptic restoration |
| Antibody |
sudden sensorineural hearing loss |
FAM19A5 |
Phase 1 |
Neuracle Science. Co., Ltd. |
RS-2024-00332473 |
|
| 2 |
Development of a Tie2-activating antibody for treating acute kidney injury (AKI) |
| Antibody |
Acute Kidney Injury |
Tie2 |
Candidate |
MabTics Co., Ltd. |
RS-2023-00217918 |
|
| 3 |
A Study on the lead optimization for the development of new antibody drugs for androgenic alopecia and alopecia areata |
| Antibody |
Hair Loss |
CXCL12 |
Lead |
Epibiotech |
HN22C0027 |
|
| 4 |
Bone-delivered therapeutic antibody for osteoporosis based on clinically verified, innovative mode of action |
| Antibody |
Osteoporosis |
Cathepsin K |
Hit |
Ewha Women's University |
HN21C0317 |
|
| 5 |
Development of T cell-recruiting bispecific antibodies targeting blood antigen-specific B cells for ABO-incompatible solid organ transplantation |
| Antibody |
Organ Failure (incompatible blood type) |
ABO BCR, CD3 |
Hit |
Korea Advanced Institute of Science and Technology |
HN21C1024 |
|
